Free Trial

Ascentage Pharma Group International (AAPG) Competitors

Ascentage Pharma Group International logo
$39.21 +0.58 (+1.50%)
As of 09/16/2025 03:04 PM Eastern

AAPG vs. SMMT, RDY, ASND, VTRS, QGEN, BBIO, MRNA, ROIV, ELAN, and VRNA

Should you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

Ascentage Pharma Group International vs. Its Competitors

Summit Therapeutics (NASDAQ:SMMT) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Ascentage Pharma Group International's return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -208.64% -181.28%
Ascentage Pharma Group International N/A N/A N/A

In the previous week, Summit Therapeutics had 23 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 25 mentions for Summit Therapeutics and 2 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 1.29 beat Summit Therapeutics' score of 1.03 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
8 Very Positive mention(s)
6 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Ascentage Pharma Group International
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

4.6% of Summit Therapeutics shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ascentage Pharma Group International has higher revenue and earnings than Summit Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit Therapeutics$700K19,229.20-$221.32M-$1.01-17.94
Ascentage Pharma Group International$134.35M27.19-$55.54MN/AN/A

Summit Therapeutics presently has a consensus price target of $33.79, indicating a potential upside of 86.46%. Given Summit Therapeutics' higher probable upside, equities analysts clearly believe Summit Therapeutics is more favorable than Ascentage Pharma Group International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
3 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Summit Therapeutics beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AAPG vs. The Competition

MetricAscentage Pharma Group InternationalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.60B$3.12B$5.73B$10.31B
Dividend YieldN/A2.36%5.90%4.63%
P/E RatioN/A21.1676.3926.51
Price / Sales27.19446.35527.15123.58
Price / CashN/A45.4037.1760.46
Price / Book81.699.6213.306.29
Net Income-$55.54M-$53.28M$3.28B$270.51M
7 Day Performance1.19%1.01%0.88%1.95%
1 Month Performance-12.85%4.58%4.67%6.33%
1 Year PerformanceN/A8.35%76.59%25.62%

Ascentage Pharma Group International Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AAPG
Ascentage Pharma Group International
N/A$39.21
+1.5%
N/AN/A$3.60B$134.35M0.00600News Coverage
Positive News
SMMT
Summit Therapeutics
3.3764 of 5 stars
$18.94
+1.8%
$33.79
+78.4%
-38.5%$13.82B$700K-18.75110Positive News
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.4256 of 5 stars
$14.65
-0.5%
$16.95
+15.7%
-7.5%$12.30B$3.81B22.2027,811Positive News
ASND
Ascendis Pharma A/S
3.1068 of 5 stars
$195.58
-1.1%
$244.36
+24.9%
+41.3%$12.10B$393.54M-37.901,017Positive News
VTRS
Viatris
1.5996 of 5 stars
$9.96
-2.1%
$10.40
+4.4%
-19.1%$11.86B$14.12B-3.4332,000
QGEN
Qiagen
4.4198 of 5 stars
$45.30
-1.7%
$49.69
+9.7%
+0.7%$10.24B$2.04B26.765,765Positive News
BBIO
BridgeBio Pharma
4.4191 of 5 stars
$51.21
-2.6%
$63.94
+24.9%
+96.6%$10.06B$235.81M-12.52400Analyst Forecast
MRNA
Moderna
4.5264 of 5 stars
$23.51
-7.4%
$41.81
+77.8%
-64.1%$9.88B$3.06B-3.125,800High Trading Volume
ROIV
Roivant Sciences
2.8008 of 5 stars
$14.08
-2.3%
$17.67
+25.5%
+17.8%$9.84B$29.05M-20.11860
ELAN
Elanco Animal Health
2.813 of 5 stars
$18.52
-1.4%
$17.33
-6.4%
+28.4%$9.33B$4.48B21.539,000Positive News
VRNA
Verona Pharma PLC American Depositary Share
2.2947 of 5 stars
$106.43
+0.0%
$109.00
+2.4%
+252.4%$8.71B$221.67M-107.5030Positive News

Related Companies and Tools


This page (NASDAQ:AAPG) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners